blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2814798

EP2814798 - METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF OREXIN-2 RECEPTOR ANTAGONISTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  07.02.2020
Database last updated on 02.09.2024
FormerThe patent has been granted
Status updated on  01.03.2019
FormerGrant of patent is intended
Status updated on  24.10.2018
FormerExamination is in progress
Status updated on  06.10.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Eisai R&D Management Co., Ltd.
6-10, Koishikawa 4-chome, Bunkyo-ku
Tokyo 112-8088 / JP
[2014/52]
Inventor(s)01 / MONIZ, George, Anthony
700 Huron Avenue, Apt. 18K
Cambridge, MA 02138 / US
02 / WILCOXEN, Annie, Zhu
18 Peter Road
North Reading, MA 01864 / US
03 / BENAYOUD, Farid
805 Forest Street
North Andover, MA 01845 / US
04 / LEE, Jaemoon
57 Argilla Road
Andover, MA 01810 / US
05 / ZHANG, Huiming
2 Dorset Circle
Andover, MA 01810 / US
06 / TERAUCHI, Taro
c/o Eisai Co., Ltd.
Tsukuba Research, Laboratories
1-3 Tokodai 5-chome
Tsukuba-shi, Ibaraki / JP
07 / TAKEMURA, Ayumi
c/o Eisai Co., Ltd.
Tsukuba Research, Laboratories
1-3 Tokodai 5-chome
Tsukuba-shi, Ibaraki / JP
08 / YOSHIDA, Yu
c/o Eisai Co., Ltd.
Tsukuba Research, Laboratories
1-3 Tokodai 5-chome
Tsukuba-shi, Ibaraki / JP
09 / TANAKA, Toshiaki
c/o Eisai Co., Ltd.
Tsukuba Research, Laboratories
1-3 Tokodai 5-chome
Tsukuba-shi, Ibaraki / JP
10 / SORIMACHI, Keiichi
c/o Eisai Co., Ltd.
Tsukuba Research, Laboratories
1-3 Tokodai 5-chome
Tsukuba-shi, Ibaraki / JP
11 / NAOE, Yoshimitsu
c/o Eisai Co., Ltd.
Tsukuba Research, Laboratories
1-3 Tokodai 5-chome
Tsukuba-shi, Ibaraki / JP
12 / KAZUTA, Yuji
c/o Eisai Co., Ltd.
Tsukuba Research, Laboratories
1-3 Tokodai 5-chome
Tsukuba-shi, Ibaraki / JP
 [2014/52]
Representative(s)HGF
1 City Walk
Leeds LS11 9DX / GB
[N/P]
Former [2019/14]HGF Limited
1 City Walk
Leeds LS11 9DX / GB
Former [2014/52]HGF Limited
Belgrave Hall
Belgrave Street
Leeds LS2 8DD / GB
Application number, filing date13706874.814.02.2013
[2019/14]
WO2013US26204
Priority number, dateUS201261600109P17.02.2012         Original published format: US 201261600109 P
[2014/52]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013123240
Date:22.08.2013
Language:EN
[2013/34]
Type: A1 Application with search report 
No.:EP2814798
Date:24.12.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 22.08.2013 takes the place of the publication of the European patent application.
[2014/52]
Type: B1 Patent specification 
No.:EP2814798
Date:03.04.2019
Language:EN
[2019/14]
Search report(s)International search report - published on:EP22.08.2013
ClassificationIPC:C07C29/147, C07C303/28, C07D239/28, C12P41/00, C07C33/50, C07C309/70, C07D239/34, C07D401/12
[2014/52]
CPC:
C07C309/73 (EP,CN,RU,US); C07C29/147 (EP,CN,RU,US); C07C303/28 (EP,CN,RU,US);
C07C303/44 (US); C07C309/66 (US); C07C69/16 (RU,US);
C07D239/34 (EP,CN,RU,US); C07D401/12 (EP,CN,US); C12P7/22 (EP,CN,US);
C07B2200/07 (US); C07C2601/02 (EP,CN,US); C07C33/36 (RU);
C07C67/03 (RU); C07D307/83 (RU) (-)
C-Set:
C07C29/147, C07C33/50 (CN,EP,US);
C07C303/28, C07C309/73 (US,CN,EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/52]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERFAHREN UND VERBINDUNGEN ZUR SYNTHESE VON OREXIN-2-REZEPTOR-ANTAGONISTEN[2014/52]
English:METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF OREXIN-2 RECEPTOR ANTAGONISTS[2014/52]
French:PROCÉDÉS ET COMPOSÉS UTILES DANS LA SYNTHÈSE D'ANTAGONISTES DU RÉCEPTEUR 2 DE L'OREXINE[2014/52]
Entry into regional phase02.09.2014National basic fee paid 
02.09.2014Designation fee(s) paid 
02.09.2014Examination fee paid 
Examination procedure02.09.2014Examination requested  [2014/52]
28.04.2015Amendment by applicant (claims and/or description)
06.10.2017Despatch of a communication from the examining division (Time limit: M04)
10.01.2018Reply to a communication from the examining division
07.02.2018Despatch of a communication from the examining division (Time limit: M04)
21.05.2018Reply to a communication from the examining division
02.11.2018Communication of intention to grant the patent
07.02.2019Fee for grant paid
07.02.2019Fee for publishing/printing paid
07.02.2019Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  06.10.2017
Opposition(s)06.01.2020No opposition filed within time limit [2020/11]
Fees paidRenewal fee
26.02.2015Renewal fee patent year 03
22.02.2016Renewal fee patent year 04
17.02.2017Renewal fee patent year 05
22.02.2018Renewal fee patent year 06
21.02.2019Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL03.04.2019
AT03.04.2019
CY03.04.2019
CZ03.04.2019
DK03.04.2019
EE03.04.2019
FI03.04.2019
HR03.04.2019
LT03.04.2019
LV03.04.2019
MC03.04.2019
MK03.04.2019
MT03.04.2019
NL03.04.2019
PL03.04.2019
RO03.04.2019
RS03.04.2019
SE03.04.2019
SI03.04.2019
SK03.04.2019
SM03.04.2019
TR03.04.2019
BG03.07.2019
NO03.07.2019
GR04.07.2019
IS03.08.2019
PT03.08.2019
[2022/32]
Former [2022/27]AL03.04.2019
AT03.04.2019
CY03.04.2019
CZ03.04.2019
DK03.04.2019
EE03.04.2019
FI03.04.2019
HR03.04.2019
LT03.04.2019
LV03.04.2019
MC03.04.2019
MT03.04.2019
NL03.04.2019
PL03.04.2019
RO03.04.2019
RS03.04.2019
SE03.04.2019
SI03.04.2019
SK03.04.2019
SM03.04.2019
TR03.04.2019
BG03.07.2019
NO03.07.2019
GR04.07.2019
IS03.08.2019
PT03.08.2019
Former [2020/49]AL03.04.2019
AT03.04.2019
CZ03.04.2019
DK03.04.2019
EE03.04.2019
FI03.04.2019
HR03.04.2019
LT03.04.2019
LV03.04.2019
MC03.04.2019
NL03.04.2019
PL03.04.2019
RO03.04.2019
RS03.04.2019
SE03.04.2019
SI03.04.2019
SK03.04.2019
SM03.04.2019
TR03.04.2019
BG03.07.2019
NO03.07.2019
GR04.07.2019
IS03.08.2019
PT03.08.2019
Former [2020/26]AL03.04.2019
AT03.04.2019
CZ03.04.2019
DK03.04.2019
EE03.04.2019
FI03.04.2019
HR03.04.2019
LT03.04.2019
LV03.04.2019
NL03.04.2019
PL03.04.2019
RO03.04.2019
RS03.04.2019
SE03.04.2019
SI03.04.2019
SK03.04.2019
SM03.04.2019
TR03.04.2019
BG03.07.2019
NO03.07.2019
GR04.07.2019
IS03.08.2019
PT03.08.2019
Former [2020/17]AL03.04.2019
AT03.04.2019
CZ03.04.2019
DK03.04.2019
EE03.04.2019
FI03.04.2019
HR03.04.2019
LT03.04.2019
LV03.04.2019
NL03.04.2019
PL03.04.2019
RO03.04.2019
RS03.04.2019
SE03.04.2019
SK03.04.2019
SM03.04.2019
TR03.04.2019
BG03.07.2019
NO03.07.2019
GR04.07.2019
IS03.08.2019
PT03.08.2019
Former [2020/14]AL03.04.2019
AT03.04.2019
CZ03.04.2019
DK03.04.2019
EE03.04.2019
FI03.04.2019
HR03.04.2019
LT03.04.2019
LV03.04.2019
NL03.04.2019
PL03.04.2019
RO03.04.2019
RS03.04.2019
SE03.04.2019
SK03.04.2019
SM03.04.2019
BG03.07.2019
NO03.07.2019
GR04.07.2019
IS03.08.2019
PT03.08.2019
Former [2020/11]AL03.04.2019
AT03.04.2019
CZ03.04.2019
DK03.04.2019
EE03.04.2019
FI03.04.2019
HR03.04.2019
LT03.04.2019
LV03.04.2019
NL03.04.2019
PL03.04.2019
RO03.04.2019
RS03.04.2019
SE03.04.2019
SK03.04.2019
BG03.07.2019
NO03.07.2019
GR04.07.2019
IS03.08.2019
PT03.08.2019
Former [2020/10]AL03.04.2019
AT03.04.2019
CZ03.04.2019
DK03.04.2019
FI03.04.2019
HR03.04.2019
LT03.04.2019
LV03.04.2019
NL03.04.2019
PL03.04.2019
RO03.04.2019
RS03.04.2019
SE03.04.2019
BG03.07.2019
NO03.07.2019
GR04.07.2019
IS03.08.2019
PT03.08.2019
Former [2020/09]AL03.04.2019
AT03.04.2019
CZ03.04.2019
DK03.04.2019
FI03.04.2019
HR03.04.2019
LT03.04.2019
LV03.04.2019
NL03.04.2019
PL03.04.2019
RS03.04.2019
SE03.04.2019
BG03.07.2019
NO03.07.2019
GR04.07.2019
IS03.08.2019
PT03.08.2019
Former [2020/04]AL03.04.2019
AT03.04.2019
CZ03.04.2019
FI03.04.2019
HR03.04.2019
LT03.04.2019
LV03.04.2019
NL03.04.2019
PL03.04.2019
RS03.04.2019
SE03.04.2019
BG03.07.2019
NO03.07.2019
GR04.07.2019
IS03.08.2019
PT03.08.2019
Former [2020/03]AL03.04.2019
AT03.04.2019
CZ03.04.2019
FI03.04.2019
HR03.04.2019
LT03.04.2019
LV03.04.2019
NL03.04.2019
PL03.04.2019
RS03.04.2019
SE03.04.2019
BG03.07.2019
NO03.07.2019
GR04.07.2019
PT03.08.2019
Former [2019/52]AL03.04.2019
CZ03.04.2019
FI03.04.2019
HR03.04.2019
LT03.04.2019
LV03.04.2019
NL03.04.2019
PL03.04.2019
RS03.04.2019
SE03.04.2019
BG03.07.2019
NO03.07.2019
GR04.07.2019
PT03.08.2019
Former [2019/51]AL03.04.2019
CZ03.04.2019
FI03.04.2019
HR03.04.2019
LT03.04.2019
LV03.04.2019
NL03.04.2019
RS03.04.2019
SE03.04.2019
BG03.07.2019
NO03.07.2019
GR04.07.2019
PT03.08.2019
Former [2019/50]AL03.04.2019
CZ03.04.2019
FI03.04.2019
HR03.04.2019
LT03.04.2019
LV03.04.2019
NL03.04.2019
RS03.04.2019
SE03.04.2019
NO03.07.2019
GR04.07.2019
PT03.08.2019
Former [2019/49]AL03.04.2019
CZ03.04.2019
FI03.04.2019
HR03.04.2019
LT03.04.2019
NL03.04.2019
SE03.04.2019
NO03.07.2019
PT03.08.2019
Former [2019/48]FI03.04.2019
LT03.04.2019
NL03.04.2019
SE03.04.2019
NO03.07.2019
PT03.08.2019
Former [2019/47]FI03.04.2019
LT03.04.2019
NL03.04.2019
NO03.07.2019
Former [2019/44]NL03.04.2019
Cited inInternational search[I]WO2008057575  (DOV PHARMACEUTICAL INC [US], et al) [I] 1 * page 97, line 15 - page 99, line 12 *;
 [A]WO2008150364  (MERCK & CO INC [US], et al) [A] 1-139* the whole document *;
 [X]  - KAZUYA YAMAGUCHI ET AL, "Construction of a cis-Cyclopropane via Reductive Radical Decarboxylation. Enantioselective Synthesis of cis- and trans-1-Arylpiperazyl-2-phenylcyclopropanes Designed as Antidopaminergic Agents", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY, (20030611), vol. 68, no. 24, doi:10.1021/JO0302206, pages 9255 - 9262, XP002512742 [X] 1 * scheme 2 * * page 9260, column 1, paragraph 3 *

DOI:   http://dx.doi.org/10.1021/JO0302206
 [X]  - VALGIMIGLI L ET AL, "THE EFFECT OF RING NITROGEN ATOMS ON THE HOMOLYTIC REACTIVITY OF PHENOLIC COMPOUNDS: UNDERSTANDING THE RADICAL-SCAVENGING ABILITY OF 5-PYRIMIDINOLS", CHEMISTRY - A EUROPEAN JOURNAL, WILEY - V C H VERLAG GMBH & CO. KGAA, WEINHEIM, DE, (20031017), vol. 9, no. 20, doi:10.1002/CHEM.200304960, ISSN 0947-6539, pages 4997 - 5010, XP009062482 [X] 84 * page 4998, column 1, last 4 lines to column 2, first 2 lines * * page 5007, column 1, paragraph 4 *

DOI:   http://dx.doi.org/10.1002/chem.200304960
by applicantUS7189715
 US2012009659
 US8101643
    - SAKURAI T. ET AL., CELL, (1998), vol. 92, pages 573 - 585
    - CHEMELLI R.M. ET AL., CELL, (1999), vol. 98, pages 437 - 451
    - S.L. BORGLAND ET AL., NEURON, (2006), vol. 49, pages 598 - 601
    - C.J. WINROW ET AL., NEUROPHARMACOLOGY, (2010), vol. 58, pages 185 - 194
    - J.R. SHOBLOCK ET AL., PSYCHOPHARMACOLOGY, (2011), vol. 215, pages 191 - 203
    - T. IDA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., (2000), vol. 270, pages 318 - 323
    - NAKATA ET AL., TETT. LETT., (1983), vol. 24, pages 2653 - 56
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.